Recombinant Human sTNF RII/TNFRSF1B (Recombinant Human soluble Tumor Necrosis Factor Receptor Type II/TNFRSF1B; rHusTNF RII/TNFRSF1B)；重组人可溶性肿瘤坏死因子受体II型/TNFRSF1B
Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the TNF-α mediated cytotoxicity in the L-929 cells is less than 0.2μg/ml, corresponding to a specific activity of >5000IU/mg in the presence of 0.25ng/ml of rHuTNF-α.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered solution in PBS, pH7.4.
Endotoxin
Less than 0.1EU/μg of rHusTNF RII/TNFRSF1B as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
Tumor Necrosis Factor Receptor-I (TNF RI, also known as p55/p60) and TNF RII (also known as p75/p80) are both high affinity receptors for TNF-alpha and -beta, potent mediators of multiple aspects of inflammatory immune responses. Both RI and RII are prototypic members of the TNF receptor superfamily and have been designated TNFRSF1A and TNFRSF1B, respectively. Whereas all cell types are thought to express TNF RI, TNF RII expression is limited primarily to hematopoietic cells and cells of the immune system. Most of the biological functions of TNF are mediated via TNF RI. Soluble forms of both TNF RI and TNF RII, generated as a result of proteolytic cleavage of the extracellular domains, have been detected in vivo in various biological fluids. The soluble TNF receptors can bind TNF with high affinity and functions as TNF antagonists.
